SOX9 and renal cell carcinoma: These data confirmed a precedent study that associated SOX9 expression with RCC Fuhrman grading and showed that patients with SOX9 (−) had a much better therapeutic response to tyrosine kinase inhibitors than those with SOX9 (+) [112].